Vertex Pharmaceuticals (VRTX) Construction in Progress (2011 - 2012)

Vertex Pharmaceuticals' (VRTX) quarterly Construction in Progress came in at $223.1 million in Q3 2012, up 305.12% quarter-over-quarter from $55.1 million in Q4 2011.

Vertex Pharmaceuticals (VRTX) Construction in Progress (2011 - 2012) Analysis & Trends

Vertex Pharmaceuticals' Construction in Progress history runs 2 years deep, the most recent figure standing at $223.1 million for Q3 2012.

  • On a quarterly basis, Construction in Progress changed N/A year-over-year to $223.1 million in Q3 2012; TTM through Sep 2012 was $223.1 million, a N/A change from a year earlier, with the FY2011 full-year figure at $55.1 million, changed N/A from the prior year.
  • Construction in Progress climbed to $223.1 million in Q3 2012 per VRTX's latest filing, from $55.1 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $223.1 million in Q3 2012 and bottomed at $55.1 million in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 137.45 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2012 223.10 Mn
Dec 31, 2011 55.07 Mn